Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Lancet. Infectious Diseases (Print)

• Publication date

  2003-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1473-3099(03)00545-0PMID 12614731
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Local Role for Tumor Necrosis Factor Alpha in the Pulmonary Inflammatory Response to Mycobacterium tuberculosis Infection

  2002cited by this paper
• Raynaud's phenomenon affecting the tongue of a patient with scleroderma

  2002cited by this paper
• TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial Infection1

  2002cited by this paper
• Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.

  2002cited by this paper
• Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial

  2002cited by this paper
• Binding and functional comparisons of two types of tumor necrosis factor antagonists.

  2002cited by this paper
• Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

  2002cited by this paper
• Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

  2002cited by this paper
• Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.

  2001cited by this paper
• Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

  2001cited by this paper
• Etanercept therapy in children with treatment-resistant uveitis.

  2001cited by this paper
• Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

  2001cited by this paper
• Effect of infliximab on threatening panuveitis in Behçet's disease.

  2001cited by this paper
• Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

  2001cited by this paper
• Infection of Human Macrophages and Dendritic Cells with Mycobacterium tuberculosis Induces a Differential Cytokine Gene Expression That Modulates T Cell Response1

  2001cited by this paper
• Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.

  2001cited by this paper
• Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

  2001cited by this paper
• Cytokine pathways and joint inflammation in rheumatoid arthritis.

  2001cited by this paper
• Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.

  2001cited by this paper
• Effects of Tumor Necrosis Factor Alpha on Host Immune Response in Chronic Persistent Tuberculosis: Possible Role for Limiting Pathology

  2001cited by this paper
• Tumor Necrosis Factor Receptor 2 Plays a Minor Role for Mycobacterial Immunity

  2000cited by this paper
• Tumor necrosis factor: biology and therapeutic inhibitors.

  2000cited by this paper
• Restraining mycobacteria: Role of granulomas in mycobacterial infections

  2000cited by this paper
• Immunopathologic Effects of Tumor Necrosis Factor Alpha in Murine Mycobacterial Infection Are Dose Dependent

  2000cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• In Situ Production of Gamma Interferon, Interleukin-4, and Tumor Necrosis Factor Alpha mRNA in Human Lung Tuberculous Granulomas

  2000cited by this paper
• Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis.

  2000cited by this paper
• Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

  2000cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• A role for lymphotoxin β receptor in host defense against Mycobacterium bovis BCG infection

  1999cited by this paper
• PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases

  1999cited by this paper
• Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin.

  1999cited by this paper
• Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.

  1999cited by this paper
• Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis.

  1999cited by this paper
• Fatal Granuloma Necrosis without Exacerbated Mycobacterial Growth in Tumor Necrosis Factor Receptor p55 Gene-Deficient Mice Intravenously Infected with Mycobacterium avium

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha.

  1998cited by this paper
• Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population.

  1998cited by this paper
• Expression of chemokines and induction of rapid cell death in human blood neutrophils by Mycobacterium tuberculosis.

  1998cited by this paper
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

  1997cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

  1997cited by this paper
• Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis

  1997cited by this paper
• The role of cytokines in the immune response to tuberculosis.

  1996cited by this paper
• Corticosteroids in Tuberculosis

  1996cited by this paper
• Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

  1995cited by this paper
• Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.

  1995cited by this paper
• Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

  1995cited by this paper
• Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis

  1995cited by this paper
• Assessment of a possible imbalance between tumor necrosis factor (TNF) and soluble TNF receptor forms in tuberculous infection of the central nervous system.

  1995cited by this paper
• Immunol. Cell Biol.

  1995cited by this paper
• Differential release of tumor necrosis factor-alpha from murine peritoneal macrophages stimulated with virulent and avirulent species of mycobacteria.

  1994cited by this paper
• Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.

  1993cited by this paper
• Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

  1993cited by this paper
• Tumor necrosis factor in the malnutrition (cachexia) of infection and cancer.

  1992cited by this paper
• Treatment of refractory rheumatoid arthritis--the thalidomide experience.

  1989cited by this paper
• Evidence that tumor necrosis factor has an important role in antibacterial resistance.

  1989cited by this paper
• The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection.

  1989cited by this paper
• Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation

  1988cited by this paper
• Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor).

  1985cited by this paper
• "Compendium of pharmaceuticals and specialties".

  1983cited by this paper
• Tuberculosis in Canada

  1944cited by this paper
• Journal of Leukocyte Biology 49:380-387 (1991) Tumor Necrosis Factor and Granulocyte Macrophage- Colony Stimulating Factor Stimulate Human Macrophages to Restrict Growth of Virulent Mycobacterium avium and to Kill Avirulent M. avium: Killing Effector Mech

  year unknowncited by this paper

• Effectiveness of tuberculosis preventive treatment in patients with rheumatic diseases: a global systematic review and meta-analysis

  2025cites this paper
• Mycobacterium tuberculosis impairs protective cytokine production via transcription factor MafB manipulation

  2025cites this paper
• Rheumatic diseases and latent tuberculosis infection in children: diagnostic and therapeutic challenges

  2025cites this paper
• Peritoneal Tuberculosis in a Patient on Tumor Necrosis Factor inhibitors: A Case Report and Review of the Literature

  2025cites this paper
• Strengthening Signal Detection in Pharmacovigilance by Using International Nonproprietary Name (INN) Stems.

  2025cites this paper
• Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised Evidence

  2025cites this paper
• Prevalence of opportunistic infections in Syrian inflammatory bowel disease patients on biologic therapy: a multi-center retrospective cross-sectional study

  2025cites this paper
• Tuberculosis risk in patients with Crohn’s disease on biologics: a retrospective analysis of the Japanese Medical Claims Database

  2024cites this paper
• Anti-inflammatory and antioxidant activity of high concentrations of hydrogen in the lung diseases: a systematic review and meta-analysis

  2024cites this paper
• Association between ambient particulate matter and latent tuberculosis infection among 198 275 students

  2024cites this paper
• Comparisons of infection events associated with tumor necrosis factor inhibitors in patients with inflammatory arthritis: A systematic review and network meta-analysis

  2024cites this paper
• Screening with urine Histoplasma antigen test in asymptomatic patients starting TNF-alpha inhibitor therapy: a cohort study

  2024cites this paper
• Candidate Blood MicroRNAs as Potential Biomarkers in Patients with Active and Latent Pulmonary Tuberculosis Infection

  2024cites this paper
• Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis

  2024cites this paper
• Growing from common ground: nontuberculous mycobacteria and bronchiectasis

  2024cites this paper
• The SH3-binding domain of chorismate mutase protein of Mycobacterium tuberculosis contributes to mycobacterial virulence

  2024cites this paper
• Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy

  2023cites this paper
• TNF promotes DECTIN2 family C-type lectin receptor expression in human macrophages.

  2023cites this paper
• Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report

  2023cites this paper
• Pediyatrik Romatoloji Hastalarında Tüberküloz Enfeksiyonu Tanısında TNF-Alfa Blokörü Kullanımı Öncesi İnterferon-Gama Salınım Testlerinin Tanısal Değeri

  2023cites this paper
• Diagnostic Value of Interferon-Gamma Release Assay in the Diagnosis of Tuberculosis Infection Before the Use of TNF-Alpha Blocker in Pediatric Rheumatology Patients

  2023cites this paper
• Nontuberculous Mycobacterial Pulmonary Disease in the Immunocompromised Host.

  2023cites this paper
• Rectal delivery of 89Zr-labeled infliximab-loaded nanoparticles enables PET imaging-guided localized therapy of inflammatory bowel disease.

  2023cites this paper
• Mycobacterium marinum: A Case-Based Narrative Review of Diagnosis and Management

  2023cites this paper
• Effectiveness of screening in patients with rheumatic disease on biological therapy and risk of active tuberculosis

  2023cites this paper
• Comment on Kridin et al.—Considering both relative and absolute risk differences in infection risk between biologics classes in patients with psoriasis

  2023cites this paper
• Risk for multidrug-resistant tuberculosis in patients treated with anti-tumor necrosis factor agents

  2023cites this paper
• Risk of Tumor Necrosis Factor Alpha Inhibitors Usage and Related Adverse Effects

  2023cites this paper
• Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study

  2022cites this paper
• Interferon (cid:2) Assays in the Diagnosis of Tuberculosis Infection in Psoriasis Patients Who Are Candidates for Biologic Therapies (cid:2) Interferon (cid:2) Assays in the Diagnosis of Tuberculosis in Psoriasis Patients

  2022cites this paper
• Targeted therapy for autoimmune diseases based on multifunctional frame nucleic acid system: blocking TNF-α-NF-κB signaling and mediating macrophage polarization

  2022cites this paper
• Cytokine‐induced transient monocyte IL‐7Ra expression and the serum milieu in tuberculosis

  2022cites this paper
• TUBERCULOSIS MILIAR EN PACIENTES EN TRATAMIENTO CON ADALIMUMAB, UNA ASOCIACIÓN NO TAN FRECUENTE EN PEDIATRÍA

  2022cites this paper
• Analysis of the Research Hotspot of Drug Treatment of Tuberculosis: A Bibliometric Based on the Top 50 Cited Literatures

  2022cites this paper
• Disseminated cutaneous Mycobacterium haemophilum infection in a patient on infliximab for rheumatoid arthritis

  2022cites this paper
• Dichotomous Role of Tumor Necrosis Factor in Pulmonary Barrier Function and Alveolar Fluid Clearance

  2022cites this paper
• Spotlight on latent tuberculosis infection screening for juvenile idiopathic arthritis in two countries, comparing high and low risk patients

  2022cites this paper
• Active and Latent Tuberculosis in Children Treated with Anti-TNF-α: A Retrospective Multicenter Study

  2022cites this paper
• A biomimetic nanocomposite made of a ginger-derived exosome and an inorganic framework for high-performance delivery of oral antibodies.

  2021cites this paper
• Treatment of Secondary Immunodeficiencies

  2021cites this paper
• Tuberculosis Clinical Presentation and Differential Diagnosis

  2021cites this paper
• The Use of Murine Infection Models to Investigate the Protective Role of TNF in Central Nervous System Tuberculosis.

  2021cites this paper
• Tuberculosis infection under anti-TNF alpha treatment.

  2021cites this paper
• Pulmonary Tuberculosis After Therapy with Anti-Tumor Necrosis Factor (TNF) for Crohn Disease: A Case Report

  2021cites this paper
• Tuberculosis endotypes to guide stratified host-directed therapy.

  2021cites this paper
• Association of Tumor Necrosis Factor α Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010–2017

  2021cites this paper
• Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study

  2021cites this paper
• Normas

  2020cites this paper
• Assessing Complexity Among Patients With Tuberculosis in California, 1993–2016

  2020cites this paper
• Tuberculin skin test conversion in patients under treatment with anti-tumor necrotizing factor alpha agents

  2020cites this paper
• A CASE SERIES OF PLEURO-PULMONARY MANIFESTATIONS IN RHEUMATOID ARTHRITIS PATIENTS AT A TERTIARY CARE HOSPITAL IN KANCHIPURAM

  2020cites this paper
• Host Genetics of Tuberculosis Susceptibility

  2020cites this paper
• Screening for Latent Tuberculosis and Biological Therapy.

  2020cites this paper
• Targeted Combination of Antioxidative and Anti-Inflammatory Therapy of Rheumatoid Arthritis using Multifunctional Dendrimer-Entrapped Gold Nanoparticles as a Platform.

  2020cites this paper
• Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden.

  2020cites this paper
• RNA interference-mediated suppression of TNF-α converting enzyme as an alternative anti-TNF-α therapy for rheumatoid arthritis.

  2020cites this paper
• Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy

  2020cites this paper
• AB1283-HPR GASTROINTESTINAL INVOLVEMENT AND QUALITY OF LIFE IN A COHORT OF SYSTEMIC SCLEROSIS (SSC) PATIENTS

  2020cites this paper
• AB1280-HPR REQUIRED FORCE TO OBTAIN A POSITIVE SQUEEZE TEST AUTOMATIZED IN PATIENTS WITH HAND ARTHRALGIA

  2020cites this paper
• Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNF‐α Inhibitors

  2020cites this paper
• Screening for Latent Tuberculosis and Biological Therapy

  2020cites this paper
• Importance of TNF-alpha and its alterations in the development of cancers.

  2020cites this paper
• The unforeseen during biotechnological therapy for moderate‐to‐severe psoriasis: How to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis, hepatitis B virus, hepatitis C virus, and HIV, surgery, vaccinations, diagnosis of malignancy, and dose tapering

  2020cites this paper
• Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report

  2020cites this paper
• Ocular complications of tumour necrosis factor alpha inhibitors

  2020cites this paper
• A 48-Year-Old South African Woman with Rheumatoid Arthritis and Lung Nodules.

  2020cites this paper
• MicroRNA-889 Inhibits Autophagy To Maintain Mycobacterial Survival in Patients with Latent Tuberculosis Infection by Targeting TWEAK

  2020cites this paper
• Tuberculosis and Biologic Therapies: Anti-Tumor Necrosis Factor-α and Beyond.

  2019cites this paper
• DDDT_A_200147 2491..2502

  2019cites this paper
• Tuberculosis in people with rheumatic disease in Finland 1995–2007: a nationwide retrospective register study

  2019cites this paper
• The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs.

  2019cites this paper
• A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment

  2019cites this paper
• Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events

  2019cites this paper
• Tuberculosis of the breast: an uncommon presentation of an old disease

  2019cites this paper
• 47-Year-Old Given BCG Vaccine as a Child

  2019cites this paper
• Latent tuberculosis and the use of immunomodulatory agents

  2019influential citation
• Interaction of mycobacteria with Plasmin(ogen) affects phagocytosis and granuloma development.

  2019cites this paper
• Polymorphisms of cytokine genes and tuberculosis in two independent studies

  2019cites this paper
• Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study

  2019cites this paper
• Molecular degree of perturbation of plasma inflammatory markers associated with tuberculosis reveals distinct disease profiles between Indian and Chinese populations

  2019cites this paper
• Enduring Challenge of Latent Tuberculosis in Older Nursing Home Residents: A Brief Review

  2019cites this paper
• Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease

  2019cites this paper
• Therapy for Crohn's Disease

  2019cites this paper
• Challenges and Advances in TB Drug Discovery

  2019cites this paper
• Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders

  2019cites this paper
• Insights into ligand binding by a viral tumor necrosis factor (TNF) decoy receptor yield a selective soluble human type 2 TNF receptor

  2019cites this paper
• Epigenetic stabilization of DC and DC precursor classical activation by TNFα contributes to protective T cell polarization

  2019cites this paper
• Pleural tuberculosis under rituximab therapy for anti-synthetase syndrome

  2018cites this paper
• Tuberculosis associated with tumor necrosis factor-α antagonists, case description and analysis of reported cases in Colombia.

  2018cites this paper
• Follow‐up of 1887 patients receiving tumor necrosis‐alpha antagonists: Tuberculin skin test conversion and tuberculosis risk

  2018cites this paper
• Ustekinumab in patients previously treated with TNFα inhibitors: a real-life study

  2018cites this paper
• Cytokine Biomarkers Associated with Human Extra-Pulmonary Tuberculosis Clinical Strains and Symptoms

  2018cites this paper
• Safety of biologics in psoriasis

  2018cites this paper
• Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice

  2018cites this paper
• Polymorphisms in TLR4 and TNFA and Risk of Mycobacterium tuberculosis Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil: A Prospective Cohort Study.

  2018cites this paper
• Screening for Latent Tuberculosis Infection in Patients who are Candidate for Biological Therapies in Spain? A Multidisciplinary Survey.

  2018cites this paper
• Prevention and treatment of tuberculosis infection in candidates for biologic therapy: A multidisciplinary consensus statement adapted to the dermatology patient.

  2018cites this paper
• TNFα inhibitors exacerbate Mycobacterium paratuberculosis infection in tissue culture: a rationale for poor response of patients with Crohn’s disease to current approved therapy

  2018cites this paper
• TB or Not TB: Crohn’s Disease, Peritoneal Tuberculosis, or Both?

  2018cites this paper
• SCIENTIFIC ADVICE Programmatic management of latent tuberculosis infection in the European Union

  2018cites this paper